At Memorial Sloan Kettering (MSK), we're not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we're driving excellence and improving outcomes. We're treating cancer, one patient at a time. Join us and make a difference every day.
In compliance with applicable New York and New Jersey State regulatory authorities, COVID-19 vaccination (2 doses of either the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine) is mandatory for all MSK employees, contingent workers, and volunteers. Exceptions are permitted for those employees who request and receive an approved medical or fully remote exemption.
*Staff working at a MSK New Jersey location must be up to date with COVID-19 vaccination, which includes having completed the primary COVID-19 vaccination series and booster once eligible as mandated by New Jersey State. All New Jersey staff not yet eligible for a booster must receive a booster within 3 weeks of becoming eligible as a condition of continued employment at MSK.
Note: Individuals are eligible to receive a COVID-19 booster five months after receiving the second dose of either the Pfizer or Moderna vaccine or two months after the J&J vaccine.
NEW YORK, NEW YORK (USA). The Department of Pathology at Memorial Sloan Kettering Cancer Center is seeking an AP or AP/CP board-certified pathologist at the rank of Assistant or Associate Attending Pathologist. Fellowship training in Cytopathology is a requirement. Additional fellowship training in Molecular Genetic, Gastrointestinal or Genitourinary Pathology is desirable but not required.
The Cytology Service, led by Dr. Oscar Lin, is composed of 13 pathologists with extensive expertise in Cytopathology supported by a large dedicated team of allied health staff and state of the art laboratory infrastructure including immunohistochemistry, flow cytometry, cytogenetics and molecular pathology laboratories. The service has an active fine needle aspiration service and utilizes telepathology systems for rapid on-site adequacy assessment. The service has an ACGME accredited fellowship program with 3-4 fellows/year. Applicants should have a strong interest in collaborative research, for which there are ample opportunities with an outstanding supportive infrastructure. Research interest in advanced molecular testing and/or digital pathology is highly desirable. Candidates will be expected to provide diagnostic services in Cytopathology, to engage in collaborative patient care and translational research with members of our world class disease management teams, and to participate in our educational programs. Eligibility for New York State and New Jersey medical licenses is a requirement.
MSKCC offers a competitive compensation package with exceptional benefits, commensurate with experience and accomplishments.
Please send a CV and letter outlining your interest to:
Ahmet Dogan, M.D., Ph.D.
Acting Chairman, Department of Pathology
MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision.
Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment.
As one of the world's premier cancer centers, Memorial Sloan-Kettering Cancer Center is committed to exceptional patient care, leading-edge research, and superb educational programs. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available today as we work to discover more effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and the biomedical research agenda around the world.